129 related articles for article (PubMed ID: 37972434)
1. Identification of Ebselen derivatives as novel SARS-CoV-2 main protease inhibitors: Design, synthesis, biological evaluation, and structure-activity relationships exploration.
Zhang H; Li J; Toth K; Tollefson AE; Jing L; Gao S; Liu X; Zhan P
Bioorg Med Chem; 2023 Dec; 96():117531. PubMed ID: 37972434
[TBL] [Abstract][Full Text] [Related]
2. The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus.
Qiao Z; Wei N; Jin L; Zhang H; Luo J; Zhang Y; Wang K
Bioorg Chem; 2021 Dec; 117():105455. PubMed ID: 34740055
[TBL] [Abstract][Full Text] [Related]
3. Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PL
Zmudzinski M; Rut W; Olech K; Granda J; Giurg M; Burda-Grabowska M; Kaleta R; Zgarbova M; Kasprzyk R; Zhang L; Sun X; Lv Z; Nayak D; Kesik-Brodacka M; Olsen SK; Weber J; Hilgenfeld R; Jemielity J; Drag M
Sci Rep; 2023 Jun; 13(1):9161. PubMed ID: 37280236
[TBL] [Abstract][Full Text] [Related]
4. Computational analysis of the interactions between Ebselen and derivatives with the active site of the main protease from SARS-CoV-2.
Rieder GS; Nogara PA; Omage FB; Duarte T; Dalla Corte CL; da Rocha JBT
Comput Biol Chem; 2023 Dec; 107():107956. PubMed ID: 37748316
[TBL] [Abstract][Full Text] [Related]
5. Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals.
Sun LY; Chen C; Su J; Li JQ; Jiang Z; Gao H; Chigan JZ; Ding HH; Zhai L; Yang KW
Bioorg Chem; 2021 Jul; 112():104889. PubMed ID: 33915460
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
Gao S; Song L; Claff T; Woodson M; Sylvester K; Jing L; Weiße RH; Cheng Y; Sträter N; Schäkel L; Gütschow M; Ye B; Yang M; Zhang T; Kang D; Toth K; Tavis J; Tollefson AE; Müller CE; Zhan P; Liu X
J Med Chem; 2022 Dec; 65(24):16902-16917. PubMed ID: 36475694
[TBL] [Abstract][Full Text] [Related]
7. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M
Hicks EG; Kandel SE; Lampe JN
Bioorg Med Chem Lett; 2022 Jun; 66():128732. PubMed ID: 35427739
[TBL] [Abstract][Full Text] [Related]
8. Discovery of antiviral SARS-CoV-2 main protease inhibitors by structure-guided hit-to-lead optimization of carmofur.
Kang KM; Jang Y; Lee SS; Jin MS; Jun CD; Kim M; Kim YC
Eur J Med Chem; 2023 Nov; 260():115720. PubMed ID: 37633203
[TBL] [Abstract][Full Text] [Related]
9. Ebselen suitably interacts with the potential SARS-CoV-2 targets: an
Sarkar C; Abdalla M; Mondal M; Khalipha ABR; Ali N
J Biomol Struct Dyn; 2022; 40(22):12286-12301. PubMed ID: 34459720
[TBL] [Abstract][Full Text] [Related]
10. Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease.
Huang C; Zeng R; Qiao J; Quan B; Luo R; Huang Q; Guo N; Li Y; Long X; Ma R; Xia A; Fang Z; Wang Y; Li Y; Zheng Y; Li L; Lei J; Yang S
Eur J Med Chem; 2023 Nov; 259():115657. PubMed ID: 37517202
[TBL] [Abstract][Full Text] [Related]
11. Determination of potential inhibitors based on isatin derivatives against SARS-CoV-2 main protease (m
Badavath VN; Kumar A; Samanta PK; Maji S; Das A; Blum G; Jha A; Sen A
J Biomol Struct Dyn; 2022 Apr; 40(7):3110-3128. PubMed ID: 33200681
[TBL] [Abstract][Full Text] [Related]
12. In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives.
Nogara PA; Omage FB; Bolzan GR; Delgado CP; Aschner M; Orian L; Teixeira Rocha JB
Mol Inform; 2021 Aug; 40(8):e2100028. PubMed ID: 34018687
[TBL] [Abstract][Full Text] [Related]
13. Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives.
Amporndanai K; Meng X; Shang W; Jin Z; Rogers M; Zhao Y; Rao Z; Liu ZJ; Yang H; Zhang L; O'Neill PM; Samar Hasnain S
Nat Commun; 2021 May; 12(1):3061. PubMed ID: 34031399
[TBL] [Abstract][Full Text] [Related]
14. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2.
Weglarz-Tomczak E; Tomczak JM; Talma M; Burda-Grabowska M; Giurg M; Brul S
Sci Rep; 2021 Feb; 11(1):3640. PubMed ID: 33574416
[TBL] [Abstract][Full Text] [Related]
15. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
16. Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity.
Hamdy R; Fayed B; Mostafa A; Shama NMA; Mahmoud SH; Mehta CH; Nayak Y; M Soliman SS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445763
[TBL] [Abstract][Full Text] [Related]
17. Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors.
Cui J; Jia J
Eur J Med Chem; 2021 Dec; 225():113789. PubMed ID: 34438124
[TBL] [Abstract][Full Text] [Related]
18. [Development of antiviral drugs based on inhibitors of the SARS-COV-2 main protease].
Sulimov AV; Shikhaliev KS; Pyankov OV; Shcherbakov DN; Chirkova VY; Ilin IS; Kutov DC; Tashchilova AS; Krysin MY; Krylskiy DV; Stolpovskaya NV; Volosnikova EA; Belenkaya SV; Sulimov VB
Biomed Khim; 2021 May; 67(3):259-267. PubMed ID: 34142533
[TBL] [Abstract][Full Text] [Related]
19. MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L.
Ma XR; Alugubelli YR; Ma Y; Vatansever EC; Scott DA; Qiao Y; Yu G; Xu S; Liu WR
ChemMedChem; 2022 Jan; 17(1):e202100456. PubMed ID: 34242492
[TBL] [Abstract][Full Text] [Related]
20. Antiviral drug discovery by targeting the SARS-CoV-2 polyprotein processing by inhibition of the main protease.
Kandeel M; Kim J; Fayez M; Kitade Y; Kwon HJ
PeerJ; 2022; 10():e12929. PubMed ID: 35186496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
